ATRC
AtriCure, Inc.
ATRC's fundamentals are strong, but it looks expensive: trading at 187x earnings, about three times its usual 61x. Analysts expect earnings to recover and profitability to improve, though they disagree widely on how much.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
ATRC Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Healthy | |
| Strong |
ATRC's revenue, profitability, cash flow and balance sheet are all currently healthy.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
ATRC PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 37x | $11.06 | -80% |
| Fair | 61x | $18.23 | -67% |
| Current | 187x | $55.98 | — |
| Expensive | 203x | $60.96 | +8.9% |
| Forward | 211x | $55.98 | — |
Historical ranges are pointers, not guarantees.
ATRC's PE is in its expensive range at 187x. On analysts' estimates for next year's earnings, today's price would be 211x.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
ATRC Forward outlook
| Metric | Outlook |
|---|---|
| Deteriorating | |
| Returning to profit | |
| Growth | |
| Strongly improving | |
| Limited | |
| Low |
ATRC has the edge over HIMS on the outlook, with more favorable earnings and profitability expectations.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
ATRC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.26 | -12% |
| Q3 2026 | $0.30 | +$0.91 |
| Q2 2026 | $0.21 | +$0.98 |
| Q1 2026 | -$0.10 | +$0.71 |
| Q4 2025 | -$0.24 | +$0.71 |
| Q3 2025 | -$0.61 | +$0.22 |
| Q2 2025 | -$0.77 | +$0.09 |
| Q1 2025 | -$0.81 | -$0.01 |
| Q4 2024 | -$0.95 | -$0.29 |
ATRC has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
ATRC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $154.5M | +15% |
| Q2 2026 | $153.6M | +13% |
| Q1 2026 | $141.2M | +14% |
| Q4 2025 | $140.5M | +13% |
| Q3 2025 | $134.3M | +16% |
| Q2 2025 | $136.1M | +17% |
| Q1 2025 | $123.6M | +14% |
| Q4 2024 | $124.3M | +17% |
ATRC's revenue has grown year over year for 23 quarters in a row: $154M last quarter, up 15% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 2.8% | +2.7 points |
| Q2 2026 | 6.3% | +11 points |
| Q1 2026 | 0.4% | +5.2 points |
| Q4 2025 | 1.8% | +14 points |
| Q3 2025 | 0.1% | +6.5 points |
| Q2 2025 | -4.5% | +1.6 points |
| Q1 2025 | -4.8% | +5.2 points |
| Q4 2024 | -12% | -3.5 points |
ATRC has the edge over HIMS on profitability, with a higher operating margin.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over ATRC on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
ATRC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $23.9M | -0.7% |
| Q2 2026 | $18.4M | -2.8% |
| Q1 2026 | -$7.8M | +$5.4M |
| Q4 2025 | $18.4M | +486% |
| Q3 2025 | $24.1M | +47% |
| Q2 2025 | $19M | +279% |
| Q1 2025 | -$13.2M | +$10.6M |
| Q4 2024 | $3.1M | +153% |
ATRC generated $53M in free cash flow over the past year, up 60% from the year before.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over ATRC on cash flow, with more consistent year-over-year improvement.
ATRC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +2% | +963K shares |
| 1 year | +4% | +1.9M shares |
| 3 years | +7.4% | +3.4M shares |
| 5 years | +8.1% | +3.7M shares |
| Available history | +33% | +12.2M shares |
ATRC has 50M diluted shares, up 4% from a year ago.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over ATRC on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
ATRC Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -3.3x | Net Cash |
| Q2 2026 | -3.2x | Net Cash |
| Q1 2026 | -4.8x | Net Cash |
| Q4 2025 | -9.5x | Net Cash |
| Q2 2022 | 0.1x | Very low |
| Q1 2022 | 0.5x | Very low |
| Q4 2021 | 0.3x | Very low |
| Q3 2021 | 0.3x | Very low |
ATRC has more cash than debt.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
ATRC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 66.5 | Neutral |
| Stochastic | 75.6 | Neutral |
ATRC's weekly RSI is 67 (neutral) and its Stochastic is 76 (neutral).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
ATRC PE vs Healthcare Sector
| Metric | ATRC | Sector median | Relative |
|---|---|---|---|
| PE | 187x | 26x | 622% above |
| PE % | 79 | 29 | 50 pts above |
ATRC is trading at 187x earnings, a 622% premium to the Healthcare sector's median of 26x.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
ATRC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $57.5 | 2.7% below |
| 20 week MA | $49.1 | 14% above |
| 50 week MA | $39.3 | 43% above |
| 100 week MA | $36.8 | 52% above |
| 200 week MA | $36.3 | 54% above |
ATRC has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
ATRC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $32.0 | $57.6 | +80% |
| 2021 | $57.6 | $73.4 | +27% |
| 2022 | $73.4 | $43.7 | -40% |
| 2023 | $43.7 | $35.7 | -18% |
| 2024 | $35.7 | $30.7 | -14% |
| 2025 | $30.7 | $40.3 | +32% |
| 2026 YTD | $40.3 | $56.0 | +39% |
ATRC has the edge over HIMS on returns for 2026, with the stronger performance.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.